PMID- 36730693
OWN - NLM
STAT- MEDLINE
DCOM- 20230816
LR  - 20240121
IS  - 2768-3613 (Electronic)
IS  - 2768-3605 (Print)
IS  - 2768-3605 (Linking)
VI  - 29
IP  - 8
DP  - 2023 Aug
TI  - Ginseng and Ginseng Herbal Formulas for Symptomatic Management of Fatigue: A 
      Systematic Review and Meta-Analysis.
PG  - 468-482
LID - 10.1089/jicm.2022.0532 [doi]
AB  - Objectives: Ginseng has been widely used in fatigue management. However, its 
      efficacy on fatigue remains unclear. This study aimed to assess the efficacy and 
      safety of ginseng and ginseng herbal formulas for fatigue in randomized clinical 
      trials (RCTs). Methods: The authors searched PubMed, Embase, Cochrane, Web of 
      Science, and Allied and Complementary Medicine Database (AMED) databases from 
      inception to July 6, 2022. Outcomes included fatigue severity, quality of life 
      (QoL), and adverse events (AEs). Quality of evidence was assessed using the 
      Cochrane Risk of Bias Tool. They pooled all included data and performed subgroup 
      analysis by fatigue type, assessment instrument, and ginseng type. Results: The 
      authors included 19 RCTs. Pooled analyses found no significant reduction in 
      fatigue severity with ginseng versus controls (standardized mean difference 
      [SMD]: -0.36, 95% confidence interval [CI]: -0.82 to 0.11, p = 0.13). In subgroup 
      analysis, there was significant fatigue reduction with the ginseng herbal formula 
      (SMD: -0.39, 95% CI: -0.66 to -0.13, p = 0.004) and chronic fatigue (CF) (SMD: 
      -0.30, 95% CI: -0.56 to -0.03, p = 0.03) compared to controls. Ginseng produced 
      significant reductions in general (i.e., non-disease-specific) fatigue compared 
      to controls (SMD: -0.48, 95% CI: -0.71 to -0.25, p < 0.0001). Ginseng was 
      associated with a trend toward QoL improvement (p = 0.05) and did not increase 
      AEs compared with controls. Effect sizes were small. Conclusion: Ginseng herbal 
      formulas improved fatigue severity compared to controls, especially among 
      patients with CF, but with a small effect size. Rigorous RCTs as well as 
      guidelines for standard ginseng usage are needed to further evaluate the effects 
      of ginseng for fatigue and ensure proper use.
FAU - Li, Xiaotong
AU  - Li X
AUID- ORCID: 0000-0003-1006-5871
AD  - Department of Medicine, Integrative Medicine Service, Memorial Sloan Kettering 
      Cancer Center, New York, NY, USA.
FAU - Yang, Mingxiao
AU  - Yang M
AD  - Department of Medicine, Integrative Medicine Service, Memorial Sloan Kettering 
      Cancer Center, New York, NY, USA.
FAU - Zhang, Yi Lily
AU  - Zhang YL
AD  - Department of Medicine, Integrative Medicine Service, Memorial Sloan Kettering 
      Cancer Center, New York, NY, USA.
FAU - Hou, Yen-Nien
AU  - Hou YN
AUID- ORCID: 0000-0002-7975-5427
AD  - Department of Medicine, Integrative Medicine Service, Memorial Sloan Kettering 
      Cancer Center, New York, NY, USA.
FAU - Smith, Colleen M
AU  - Smith CM
AD  - Department of Medicine, Integrative Medicine Service, Memorial Sloan Kettering 
      Cancer Center, New York, NY, USA.
FAU - Korenstein, Deborah
AU  - Korenstein D
AD  - Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, 
      USA.
FAU - Mao, Jun J
AU  - Mao JJ
AD  - Department of Medicine, Integrative Medicine Service, Memorial Sloan Kettering 
      Cancer Center, New York, NY, USA.
LA  - eng
GR  - P30 CA008748/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20230201
PL  - United States
TA  - J Integr Complement Med
JT  - Journal of integrative and complementary medicine
JID - 9918283075806676
SB  - IM
MH  - Humans
MH  - *Panax
MH  - Quality of Life
MH  - *Complementary Therapies
MH  - Randomized Controlled Trials as Topic
PMC - PMC10457628
OTO - NOTNLM
OT  - efficacy
OT  - fatigue
OT  - ginseng
OT  - herbal medicine
OT  - safety
COIS- The authors declare the following financial interests/personal relationships 
      which may be considered as potential competing interests: J.J.M. reports grants 
      from Tibet CheeZheng Tibetan Medicine Co. Ltd. and from Zhongke Health 
      International LLC outside the submitted work. D.K. discloses that her spouse 
      serves on the scientific advisory board of Vedanta Biosciences and has equity 
      interest, serves on the scientific advisory board of PFL-NYC, and provides 
      consulting for Fimbrion. The remaining authors declare no conflicts of interest.
EDAT- 2023/02/03 06:00
MHDA- 2023/08/16 06:43
PMCR- 2024/08/01
CRDT- 2023/02/02 15:13
PHST- 2024/08/01 00:00 [pmc-release]
PHST- 2023/08/16 06:43 [medline]
PHST- 2023/02/03 06:00 [pubmed]
PHST- 2023/02/02 15:13 [entrez]
AID - 10.1089/jicm.2022.0532 [pii]
AID - 10.1089/jicm.2022.0532 [doi]
PST - ppublish
SO  - J Integr Complement Med. 2023 Aug;29(8):468-482. doi: 10.1089/jicm.2022.0532. 
      Epub 2023 Feb 1.